Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.

Bioorganic & medicinal chemistry letters (2007-05-26)
Naohisa Ogo, Shinya Oishi, Kenji Matsuno, Jun-ichi Sawada, Nobutaka Fujii, Akira Asai
RESUMEN

Inhibition of Eg5 represents a novel approach for the treatment of cancer. Here, we report the synthesis and structure-activity relationship of S-trityl-L-cysteine (STLC) derivatives as Eg5 inhibitors. Some of these derivatives such as 4f demonstrated enhanced inhibitory activity against Eg5 and induced mitotic arrest with characteristic monoastral spindles in HeLa cells.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
L-Cysteine, 97%
Sigma-Aldrich
L-Cysteine, from non-animal source, BioReagent, suitable for cell culture, ≥98%
SAFC
L-Cysteine
Sigma-Aldrich
L-Cysteine, BioUltra, ≥98.5% (RT)
Sigma-Aldrich
L-Cysteine, ≥97%, FG
Sigma-Aldrich
Fmoc-Cys(Trt)-OH, ≥95.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
S-Methyl-L-cysteine, substrate for methionine sulfoxide reductase A
Sigma-Aldrich
S-Carboxymethyl-L-cysteine
Sigma-Aldrich
Boc-Cys(Trt)-OH, 97%
Sigma-Aldrich
S-Benzyl-L-cysteine, 97%